Intercept Pharmaceuticals


Coordinates: 40°40′43″N 78°14′35″W / 40.678631°N 78.243038°W / 40.678631; -78.243038

Intercept Pharmaceuticals
TypePublic company
Nasdaq: ICPT
Russell 2000 Component
Key people
Mark Pruzanski
(President and CEO)
Paolo Fundarò
(Chairman of the Board of Directors)
RevenueIncrease $250.2 Million(2019)[1]

Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis (PBC) now called primary biliary cholangitis, non-alcoholic fatty liver disease (or non-alcoholic steatohepatitis, NASH), cirrhosis, portal hypertension, primary sclerosing cholangitis and also the intestinal disorder, bile acid diarrhea.


The company's lead product is obeticholic acid, OCA, also known as 6-ethyl-chenodeoxycholic acid or INT-747, marketed as Ocaliva. OCA is a potent first-in-class farnesoid X receptor (FXR) agonist. As of March 2017, Ocaliva is approved in the US and the EU for use in primary biliary cholangitis. It is in phase III studies for non-alcoholic steatohepatitis (NASH) and phase II studies for primary sclerosing cholangitis.

Other products in the development pipeline include INT-767, a dual FXR/TGR5 agonist, and INT-777, a TGR5 agonist.

On June 29, 2020, the company released a statement announcing that FDA had rejected its lead product obeticholic acid, OCA, because FDA officials had determined that "the predicted benefit of the drug does not sufficiently outweigh the predicted risks".[2]

Initial public offering and stock history

Intercept trades on the NASDAQ exchange under the ticker symbol ICPT. The initial public offering of the stock on October 16, 2012 was at $15.[3] A follow-on public offering at $33 took place on June 24, 2013.

On January 9, 2014, the stock skyrocketed from $72.39 to $275.49, or about 280%, after a planned interim analysis by the independent data safety monitoring board showed that Obeticholic acid met the main goal (improvement of liver histology) at the mid-stage in the FLINT trial in NASH, sponsored by NIDDK.[4][5] The stock continued to climb to $497 over the next few days before falling back to around $317 on March 29, 2014, giving a market capitalization of around $6.2 billion.

In March 2014, the company released the results of the POISE study of Obeticholic acid in PBC, which showed the drug met the trial's primary endpoint of a reduction in serum alkaline phosphatase, a biomarker for the disease.[6] These results were presented at an international liver meeting in April 2014.[7]

As of 31 December 2014, the company has 136 employees.[8]


  1. ^
  2. ^
  3. ^ "Intercept Pharmaceuticals: Strong Biopharmaceutical IPO". Seeking Alpha. October 14, 2012. Retrieved 2014-03-21.
  4. ^ "The Farnesoid X Receptor (FXR) Ligand Obeticholic Acid in NASH Treatment Trial(FLINT)". Archived from the original on 2014-01-10.
  5. ^ Intercept Pharma. "Press release: Intercept Announces NASH Primary Endpoint Met: FLINT Trial Stopped Early for Efficacy Based on Highly Statistically Significant Improvement in Liver Histology". Archived from the original on November 29, 2014. Retrieved January 9, 2014.
  6. ^ Intercept Pharma. "Press release: Intercept Announces Positive Pivotal Phase 3 POISE Trial Results". Archived from the original on March 26, 2014. Retrieved March 27, 2014.
  7. ^ "Intercept's liver disease drug proves highly effective in study". Reuters. April 12, 2014. Retrieved April 14, 2014.
  8. ^ Intercept Pharmaceuticals. "Form 10-k: Annual report 2014". Retrieved October 2, 2015.

External links

  • "Intercept pharmaceuticals website".